GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
ES2283012T3
(es)
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
Bacterioferritina de helicobacter pylori.
|
US6913749B2
(en)
|
1998-11-02 |
2005-07-05 |
Resistentia Pharmaceuticals Ab |
Immunogenic polypeptides for inducing anti-self IgE responses
|
WO2000050006A2
(en)
|
1999-02-26 |
2000-08-31 |
Chiron Corporation |
Microemulsions with adsorbed macromoelecules and microparticles
|
AU5885700A
(en)
*
|
1999-06-22 |
2001-01-09 |
Chiron Corporation |
Method for treating chronic hbv infection
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB9923176D0
(en)
*
|
1999-09-30 |
1999-12-01 |
Smithkline Beecham Biolog |
Novel composition
|
AU772617B2
(en)
*
|
1999-11-19 |
2004-05-06 |
Csl Limited |
Vaccine compositions
|
IT1307281B1
(it)
*
|
1999-11-25 |
2001-10-30 |
Simonelli Giuseppe |
Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
|
PL211151B1
(pl)
|
2000-10-18 |
2012-04-30 |
Glaxosmithkline Biolog Sa |
Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
|
EP2277894A1
(de)
|
2000-10-27 |
2011-01-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäure und Proteine von Gruppen A und B Streptokokken
|
US7776523B2
(en)
|
2000-12-07 |
2010-08-17 |
Novartis Vaccines And Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
SK15762003A3
(sk)
|
2001-06-29 |
2005-01-03 |
Chiron Corporation |
Kompozícia vakcíny HCV E1E2
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US20030138434A1
(en)
*
|
2001-08-13 |
2003-07-24 |
Campbell Robert L. |
Agents for enhancing the immune response
|
US20030119774A1
(en)
*
|
2001-09-25 |
2003-06-26 |
Marianna Foldvari |
Compositions and methods for stimulating an immune response
|
JP4646516B2
(ja)
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
GB0210682D0
(en)
*
|
2002-05-09 |
2002-06-19 |
Glaxosmithkline Biolog Sa |
Novel use
|
AU2008200068B2
(en)
*
|
2002-06-10 |
2009-10-29 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
JP2005535308A
(ja)
|
2002-06-13 |
2005-11-24 |
カイロン コーポレイション |
Hml−2ポリペプチド発現用ベクター
|
JP4726485B2
(ja)
*
|
2002-08-02 |
2011-07-20 |
大日本住友製薬株式会社 |
細菌細胞壁骨格成分製剤
|
KR20060116037A
(ko)
*
|
2002-08-26 |
2006-11-13 |
화이자 프로덕츠 인코포레이티드 |
소의 호흡기 및 생식기계 감염에 대한 백신
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
CN1809380B
(zh)
|
2002-10-11 |
2010-05-12 |
启龙有限公司 |
广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
|
WO2004037189A2
(en)
|
2002-10-23 |
2004-05-06 |
Glaxosmithkline Biologicals S.A. |
Methods for vaccinating against malaria
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2263687B1
(de)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogene zusammensetzungen enthaltend phospholipid
|
CN102319427A
(zh)
|
2003-01-30 |
2012-01-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
SI1613346T1
(sl)
|
2003-04-04 |
2013-02-28 |
Pah Usa 15 Llc |
Mikrofluidizirane emulzije olja v vodi in sestava cepiv
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
CN1798548B
(zh)
|
2003-06-02 |
2010-05-05 |
诺华疫苗和诊断公司 |
基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
RU2378010C2
(ru)
|
2003-10-02 |
2010-01-10 |
Новартис Вэксинес Энд Дайэгностикс С.Р.Л. |
Жидкие вакцины для множественных серогрупп менингококков
|
EP1722815A1
(de)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza-virus-vakzine
|
DK1742659T3
(da)
*
|
2004-04-05 |
2013-06-03 |
Zoetis P Llc |
Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger
|
CA2564180A1
(en)
*
|
2004-04-22 |
2005-11-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
Pharmaceutical preparation containing bacterial cell wall skeleton component
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
MXPA06011994A
(es)
|
2004-04-30 |
2007-01-25 |
Chiron Srl |
Vacunacion con conjugado de meningococos.
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2811027A1
(de)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus-Vektoren für RSV- und PIV-Impfstoffe
|
CA2571421A1
(en)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Compounds for immunopotentiation
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
EP2433647A3
(de)
|
2005-01-27 |
2012-06-06 |
Children's Hospital & Research Center at Oakland |
Gna1870-basierte vesikelimpfstoffe für breitbandschutz gegen neisseria meningitidis-bedingte erkrankungen
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
CA2598488A1
(en)
|
2005-02-18 |
2006-08-31 |
Novartis Vaccines And Diagnostics, Inc. |
Immunogens from uropathogenic escherichia coli
|
HUE027400T2
(en)
|
2005-02-18 |
2016-10-28 |
Glaxosmithkline Biologicals Sa |
Proteins and nucleic acids from meningitis / sepsis with Escherichia coli
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1863529A1
(de)
*
|
2005-03-23 |
2007-12-12 |
GlaxoSmithKline Biologicals S.A. |
Neue zusammensetzung
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
ME00485B
(me)
*
|
2005-10-07 |
2011-10-10 |
Zoetis Services Llc |
VAKCINE l METODE LIJEČENJA INFLUENCE KOD CANINA
|
US20110223197A1
(en)
|
2005-10-18 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and Systemic Immunization with Alphavirus Replicon Particles
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
PL2368572T3
(pl)
|
2005-11-04 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
EP1969001A2
(de)
|
2005-11-22 |
2008-09-17 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus- und sapovirus-antigene
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
*
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NO345368B1
(no)
|
2005-12-22 |
2021-01-04 |
Glaxosmithkline Biologicals Sa |
Streptococcus pneumoniae immunogen sammensetning for anvendelse ved behandling eller forebygging av sykdommer forårsaket av Streptococcus pneumoniae infeksjon ved serotype 19A-stammer.
|
EP2357184B1
(de)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazochinoxalinverbindungen als Immunmodulatoren
|
BRPI0710210A2
(pt)
|
2006-03-30 |
2011-05-24 |
Glaxomithkline Biolog S A |
composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
MX2009000660A
(es)
|
2006-07-17 |
2009-04-08 |
Glaxosmithkline Biolog Sa |
Vacuna de influenza.
|
CA2659552A1
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
HUE037808T2
(hu)
|
2006-09-26 |
2018-09-28 |
Infectious Disease Res Inst |
Szintetikus adalékanyagot tartalmazó vakcina kompozíció
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
EP2086582B1
(de)
|
2006-10-12 |
2012-11-14 |
GlaxoSmithKline Biologicals s.a. |
Impfstoff mit einem öl-in-wasser-emulsionshilfsstoff
|
CA2664619C
(en)
|
2006-10-12 |
2012-12-11 |
Glaxosmithkline Biologicals S.A. |
Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
|
AU2008223951B2
(en)
|
2007-03-02 |
2014-03-27 |
Glaxosmithkline Biologicals S.A. |
Novel method and compositions
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
CN101784282B
(zh)
|
2007-06-26 |
2015-07-08 |
葛兰素史密丝克莱恩生物有限公司 |
包含肺炎链球菌荚膜多糖缀合物的疫苗
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
PT2173376E
(pt)
*
|
2007-08-02 |
2015-07-30 |
Biondvax Pharmaceuticals Ltd |
Vacinas de influenza multiepitópicas multiméricas
|
US9066899B2
(en)
|
2007-08-13 |
2015-06-30 |
Glaxosmithkline Biologicals Sa |
Vaccines
|
AU2008299376B2
(en)
|
2007-09-12 |
2013-02-28 |
Glaxosmithkline Biologicals S.A. |
GAS57 mutant antigens and GAS57 antibodies
|
JP2011506334A
(ja)
|
2007-12-07 |
2011-03-03 |
ノバルティス アーゲー |
免疫応答を誘導するための組成物
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
EP2234637A2
(de)
*
|
2007-12-21 |
2010-10-06 |
GlaxoSmithKline Biologicals S.A. |
Malaria-impfstoffe
|
AU2008339551B2
(en)
|
2007-12-21 |
2013-10-24 |
Glaxosmithkline Biologicals S.A. |
Mutant forms of streptolysin O
|
NZ587382A
(en)
|
2008-02-21 |
2012-01-12 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
EP2265640B1
(de)
|
2008-03-10 |
2015-11-04 |
Children's Hospital & Research Center at Oakland |
Chimere faktor-h-bindende proteine (fhbp), die eine heterologe b-domäne enthalten, und anwendungsverfahren
|
RS54306B1
(en)
|
2008-04-16 |
2016-02-29 |
Glaxosmithkline Biologicals S.A. |
THE VACCINE
|
AU2009248810B2
(en)
|
2008-05-23 |
2013-12-05 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
JP5722782B2
(ja)
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
JP2012510289A
(ja)
|
2008-12-03 |
2012-05-10 |
プロティア ワクチン テクノロジーズ リミテッド |
グルタミルtRNA合成酵素(GtS)フラグメント
|
CN102245198B
(zh)
|
2008-12-09 |
2016-08-17 |
辉瑞疫苗有限责任公司 |
IgE CH3肽疫苗
|
CN103897045A
(zh)
|
2009-01-12 |
2014-07-02 |
诺华股份有限公司 |
抗***疫苗中的Cna_B结构域
|
JP5642712B2
(ja)
|
2009-02-10 |
2014-12-17 |
ノバルティス アーゲー |
少ない量のスクアレンを含むインフルエンザワクチン
|
SG173194A1
(en)
*
|
2009-02-17 |
2011-09-29 |
Glaxosmithkline Biolog Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
EP3549602A1
(de)
|
2009-03-06 |
2019-10-09 |
GlaxoSmithKline Biologicals S.A. |
Chlamydia-antigene
|
BRPI1013780B8
(pt)
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
|
BRPI1014494A2
(pt)
|
2009-04-30 |
2016-08-02 |
Coley Pharm Group Inc |
vacina pneumocócica e usos da mesma
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
BRPI1011072B1
(pt)
|
2009-06-05 |
2021-09-28 |
Infectious Disease Research Institute |
Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
|
CN102802665B
(zh)
|
2009-06-15 |
2015-11-25 |
新加坡国立大学 |
流感疫苗、组合物及使用方法
|
WO2010148111A1
(en)
|
2009-06-16 |
2010-12-23 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
EP2451833B1
(de)
|
2009-07-07 |
2018-01-17 |
GlaxoSmithKline Biologicals SA |
Konservierte escherichia-coli-immunogene
|
EP2464658B1
(de)
|
2009-07-16 |
2014-10-01 |
Novartis AG |
Detoxifizierte escherichia coli immunogene
|
KR20130127547A
(ko)
|
2009-07-30 |
2013-11-22 |
화이자 백신스 엘엘씨 |
항원성 타우 펩타이드 및 이의 용도
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
WO2011018504A2
(en)
*
|
2009-08-12 |
2011-02-17 |
Sigmoid Pharma Limited |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
ES2562259T3
(es)
|
2009-08-27 |
2016-03-03 |
Glaxosmithkline Biologicals Sa |
Polipéptidos híbridos que incluyen secuencias fHBP meningocócicas
|
SG178447A1
(en)
|
2009-09-03 |
2012-03-29 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
WO2011031139A1
(en)
|
2009-09-09 |
2011-03-17 |
Universiteit Utrecht Holding B.V. |
An ataq protein or a part thereof as a vaccine
|
US9107859B2
(en)
*
|
2009-09-10 |
2015-08-18 |
Merial, Inc. |
Vaccine formulations comprising saponin-containing adjuvants
|
AU2010293902A1
(en)
|
2009-09-10 |
2012-03-22 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
CA2776004A1
(en)
|
2009-09-30 |
2011-04-07 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
JP2013506651A
(ja)
|
2009-09-30 |
2013-02-28 |
ノバルティス アーゲー |
Staphylococcus.aureus5型および8型莢膜多糖の結合体
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
EP2493499A1
(de)
|
2009-10-27 |
2012-09-05 |
Novartis AG |
Modifizierte meningokokken-fhbp-polypeptide
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
SA110310855B1
(ar)
|
2009-11-13 |
2014-09-16 |
Laboratories Leti S L Unipersonal |
استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
WO2011077309A2
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Vaccines Llc |
Vaccine compositions
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
EP2353609A1
(de)
|
2010-02-04 |
2011-08-10 |
Sanofi Pasteur |
Immunisierungszusammensetzungen und -verfahren
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
CN105315351A
(zh)
|
2010-03-30 |
2016-02-10 |
奥克兰儿童医院及研究中心 |
改性的h因子结合蛋白(fhbp)及其使用方法
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011127316A1
(en)
|
2010-04-07 |
2011-10-13 |
Novartis Ag |
Method for generating a parvovirus b19 virus-like particle
|
EP2566506B1
(de)
*
|
2010-05-07 |
2016-07-06 |
Virbac |
Zusammensetzung eines impfstoffs zur verhinderung oder behandlung von leishmaniose
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
EP2575868A1
(de)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige-ch3-peptidimpfstoff
|
US8895017B2
(en)
|
2010-06-07 |
2014-11-25 |
Pfizer Inc. |
HER-2 peptides and vaccines
|
GB201009671D0
(en)
*
|
2010-06-10 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel process
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
JP2013533745A
(ja)
|
2010-07-06 |
2013-08-29 |
ノバルティス アーゲー |
ノロウイルスに由来する免疫原性組成物および方法
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
US9187751B2
(en)
|
2010-11-10 |
2015-11-17 |
Laboratorios Leti, S.L. |
Adjuvant
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
JP6054942B2
(ja)
|
2011-04-08 |
2016-12-27 |
イミューン デザイン コーポレイション |
免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
|
ES2687129T3
(es)
|
2011-07-25 |
2018-10-23 |
Glaxosmithkline Biologicals Sa |
Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
|
CA2845872C
(en)
|
2011-08-22 |
2023-03-28 |
Nanobio Corporation |
Herpes simplex virus nanoemulsion vaccine
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2753354A4
(de)
|
2011-09-09 |
2015-04-15 |
Nanobio Corp |
Untereinheitsimpfstoff in nanoemulsionsform für das respiratorische synzytialvirus
|
US9511130B2
(en)
|
2011-09-14 |
2016-12-06 |
Glaxosmithkline Biologicals Sa |
Escherichia coli vaccine combination
|
EP2755683B1
(de)
|
2011-09-14 |
2019-04-03 |
GlaxoSmithKline Biologicals SA |
Verfahren zur herstellung von saccharidprotein-glykokonjugaten
|
EP3617227A3
(de)
|
2011-09-16 |
2020-06-03 |
UCB Biopharma SRL |
Neutralisierende antikörpern gegen das haupt exotoxin tcda von clostridium difficile
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2788477A2
(de)
|
2011-12-07 |
2014-10-15 |
Institut Pasteur |
Identifizierung des porcinen parecho-like virus und anwendungen
|
CA2858519A1
(en)
|
2011-12-08 |
2013-06-13 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
RS58868B1
(sr)
|
2012-02-07 |
2019-08-30 |
Infectious Disease Res Inst |
Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
|
WO2013124473A1
(en)
|
2012-02-24 |
2013-08-29 |
Novartis Ag |
Pilus proteins and compositions
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
CA2871520C
(en)
|
2012-04-26 |
2020-12-29 |
Novartis Ag |
Antigens from non-typeable h. influenzae
|
EP2659906A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2659908A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2659907A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2844282B1
(de)
|
2012-05-04 |
2019-06-12 |
Pfizer Inc |
Prostata-assoziierte antigene und immuntherapieschemata auf impfstoffbasis
|
KR102136433B1
(ko)
|
2012-05-16 |
2020-07-22 |
이뮨 디자인 코포레이션 |
Hsv-2 백신
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
KR20150036593A
(ko)
|
2012-07-24 |
2015-04-07 |
사노피 파스퇴르 |
뎅기열 바이러스 감염 예방용 백신 조성물
|
AU2013295014B2
(en)
|
2012-07-24 |
2018-01-18 |
Sanofi Pasteur |
Vaccine compositions
|
AU2013320313B2
(en)
|
2012-09-18 |
2018-07-12 |
Glaxosmithkline Biologicals Sa |
Outer membrane vesicles
|
EA201590427A1
(ru)
|
2012-10-02 |
2015-09-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Нелинейные сахаридные конъюгаты
|
RU2015106791A
(ru)
|
2012-10-03 |
2016-11-20 |
Глэксосмитиклайн Байолоджикалз Са |
Иммуногенные композиции
|
CA2888982C
(en)
|
2012-10-24 |
2020-07-21 |
Platelet Targeted Therapeutics, Llc |
Platelet targeted treatment
|
BR112015012515B1
(pt)
|
2012-11-30 |
2023-04-11 |
Sanofi Pasteur |
Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
|
LT2925355T
(lt)
|
2012-11-30 |
2018-03-26 |
Glaxosmithkline Biologicals S.A. |
Pseudomonas antigenai ir antigenų deriniai
|
EP3711768A1
(de)
|
2013-04-18 |
2020-09-23 |
Immune Design Corp. |
Gla-monotherapie zur verwendung in der krebsbehandlung
|
EP2996718B1
(de)
|
2013-05-15 |
2020-01-15 |
The Governors of the University of Alberta |
E1e2-hcv-impfstoffe und verfahren zur verwendung
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
KR101977449B1
(ko)
|
2013-11-01 |
2019-05-10 |
유니버시티에트 이 오슬로 |
알부민 변이체 및 이의 용도
|
KR102006527B1
(ko)
|
2013-11-01 |
2019-08-02 |
화이자 인코포레이티드 |
전립선-연관 항원의 발현을 위한 벡터
|
WO2015070207A2
(en)
|
2013-11-11 |
2015-05-14 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
|
CA2929126C
(en)
|
2013-11-13 |
2020-01-07 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
US20160287696A1
(en)
|
2013-11-20 |
2016-10-06 |
La Jolla Institute For Allergy And Immunology |
Pan pollen immunogens and methods and uses for immune response modulation
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
JP6741580B2
(ja)
|
2013-12-31 |
2020-08-19 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
単一バイアルのワクチン製剤
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3607966A1
(de)
|
2014-01-21 |
2020-02-12 |
Pfizer Inc |
Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen und verwendungen davon
|
WO2015112485A1
(en)
|
2014-01-21 |
2015-07-30 |
Immune Design Corp. |
Compositions for use in the treatment of allergic conditions
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
EP4074726A3
(de)
|
2014-07-23 |
2022-11-23 |
Children's Hospital & Research Center at Oakland |
Faktor-h-bindende proteinvarianten und verfahren zur verwendung davon
|
US11083788B2
(en)
|
2014-10-10 |
2021-08-10 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
BR112017013891B1
(pt)
|
2015-01-15 |
2024-01-30 |
Pfizer Inc |
Composições imunogênicas para uso em vacinas pneumocócicas
|
WO2016141320A2
(en)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
AU2016271857B2
(en)
|
2015-06-03 |
2020-05-28 |
Affiris Ag |
IL-23-P19 vaccines
|
EP3319988A1
(de)
|
2015-07-07 |
2018-05-16 |
Affiris AG |
Impfstoffe zur behandlung und prävention von ige-vermittelten krankheiten
|
CA2936378A1
(en)
|
2015-07-21 |
2017-01-21 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP3349790A1
(de)
|
2015-09-18 |
2018-07-25 |
Rijksuniversiteit Groningen |
Langkettiges inulin zur stimulierung einer immunantwort
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
DK3405212T3
(da)
|
2016-01-19 |
2020-08-24 |
Pfizer |
Cancervacciner
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
US11319383B2
(en)
|
2016-03-14 |
2022-05-03 |
Universitetet | Oslo |
Engineered immunoglobulins with altered FcRn binding
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
CA3034124A1
(en)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
US11466292B2
(en)
|
2016-09-29 |
2022-10-11 |
Glaxosmithkline Biologicals Sa |
Compositions and methods of treatment
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
RU2762723C2
(ru)
|
2017-01-20 |
2021-12-22 |
Пфайзер Инк. |
Иммуногенные композиции для применения в пневмококковых вакцинах
|
CA3066915A1
(en)
|
2017-06-11 |
2018-12-20 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
KR20200028395A
(ko)
|
2017-06-15 |
2020-03-16 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
US20210069319A1
(en)
|
2017-09-07 |
2021-03-11 |
University Of Oslo |
Vaccine molecules
|
JP2020533338A
(ja)
|
2017-09-07 |
2020-11-19 |
ユニバーシティ オブ オスロUniversity of Oslo |
ワクチン分子
|
CN111526885A
(zh)
|
2017-11-03 |
2020-08-11 |
武田疫苗股份有限公司 |
寨卡疫苗和免疫原性组合物及其使用方法
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
BR112020024285A2
(pt)
|
2018-06-12 |
2021-03-02 |
Glaxosmithkline Biologicals S.A. |
polinucleotídeos e polipeptídeos de adenovírus
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
CN112912097A
(zh)
|
2018-08-23 |
2021-06-04 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性蛋白和组合物
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
JP2022524007A
(ja)
|
2019-03-05 |
2022-04-27 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
B型肝炎免疫化レジメンおよび組成物
|
EP3952906A1
(de)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
|
CN114340665A
(zh)
|
2019-05-25 |
2022-04-12 |
传染病研究所 |
用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
|
EP3770269A1
(de)
|
2019-07-23 |
2021-01-27 |
GlaxoSmithKline Biologicals S.A. |
Quantifizierung von biokonjugatglykosylierung
|
EP4051696A1
(de)
|
2019-11-01 |
2022-09-07 |
Pfizer Inc. |
Escherichia-zusammensetzungen und verfahren dafür
|
KR20220097396A
(ko)
*
|
2019-11-05 |
2022-07-07 |
아쥬반스 테크놀로지스 인코포레이티드 |
바리셀라 조스터
|
CN111057738A
(zh)
*
|
2020-01-02 |
2020-04-24 |
浙江大学 |
C2c12细胞在疫苗佐剂机制研究中的用途和研究分析方法
|
CA3165957A1
(en)
|
2020-01-24 |
2021-07-29 |
Thomas K. EQUELS |
Methods, compositions, and vaccines for treating a virus infection
|
MX2022010355A
(es)
|
2020-02-21 |
2022-09-21 |
Pfizer |
Purificacion de sacaridos.
|
CA3173729A1
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
EP4240410A1
(de)
|
2020-11-04 |
2023-09-13 |
Pfizer Inc. |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
MX2023009728A
(es)
|
2021-02-19 |
2023-08-30 |
Sanofi Pasteur Inc |
Vacuna recombinante meningococica b.
|
US20240159738A1
(en)
|
2021-03-16 |
2024-05-16 |
Osaka University |
Novel medical technique using follicular t-cells
|
JPWO2022196699A1
(de)
|
2021-03-16 |
2022-09-22 |
|
|
AU2022281543A1
(en)
|
2021-05-28 |
2023-11-23 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|